ABSTRACT
Background Symptoms related to mood and anxiety disorders often present in childhood and adolescence. Some of the genetic liability for mental disorders, and emotional and behavioral difficulties seems to be shared. Yet, it is unclear how genetic liability for mood and anxiety disorders influence trajectories of childhood emotional and behavioral difficulties, and if specific developmental patterns associate with higher genetic liability for these disorders.
Methods This study uses data from a genotyped sample of children (n = 54,839) from the Norwegian Mother, Father and Child Cohort Study (MoBa). We use latent growth models (1.5-5 years) and latent profile analyses (1.5-8 years) to quantify childhood trajectories and profiles of emotional and behavioral difficulties and diagnoses. We examine associations between these trajectories and profiles with polygenic scores for bipolar disorder (PGSBD), anxiety (PGSANX), depression (PGSDEP), and neuroticism (PGSNEUR).
Results Associations between PGSDEP, PGSANX and PGSNEUR, and emotional and behavioral difficulties in childhood were developmentally stable rather than age specific. Higher PGSANX and PGSDEP were associated with steeper increases in behavioral difficulties across early childhood. Latent profile analyses identified five profiles. All PGS were associated with probability of classification into profiles characterized by some form of difficulties (vs. a normative reference profile), but only PGSBD was uniquely associated with a single developmental profile.
Conclusions Our findings indicate that genetic risk for mood disorders and related traits contribute to a more rapidly increasing and higher overall burden of emotional and behavioral difficulties across early and middle childhood, with some indications for disorder-specific profiles. These findings of associations between childhood trajectories and symptom profiles and genetic and clinical susceptibility for mental disorders, may form the basis for more targeted early interventions.
Competing Interest Statement
Ole Andreassen has received speakers honorarium from Lundbeck, Janssen, Otsaka, and Sunovion, and is a consultant of Cortechs.ai. The other authors declare no conflicts of interest.
Funding Statement
MoBa is supported by the Norwegian Ministry of Health and Care Services and is part of the HARVEST collaboration, supported by the Research Council of Norway (RCN) (#229624). MoBa also received genotype data from the NORMENT Centre funded by RCN (#223273), South East Norway Health Authorities and Stiftelsen Kristian Gerhard Jebsen. They also received genetic data from the Center for Diabetes Research, the University of Bergen (UiB) funded by the ERC AdG project SELECTionPREDISPOSED, Stiftelsen Kristian Gerhard Jebsen, Trond Mohn Foundation, RCN, the Novo Nordisk Foundation, UiB, and the Western Norway Health Authoritie. deCODE genetics provided the majority of the genotyping in MoBa. N.R.B, N.P, P.P, A.S, G.H, E.F and O.A.A was supported by grants from RCN (#271555/F21, #300309, #324252, #326813, #324499), N.P, P.P, E.H and V.B was supported by grants from European Union's Horizon 2020 research and innovation program (RealMent; #964874, #801133, #964874), P.J and A.S was supported by grants from the European Economic Area and Norway Grants (#EEA-RO-NO-2018-0535, #EEA-RO-NO-2018-0573). AH, LJH and LH was supported by funding from the South-Eastern Norway Regional Health Authority (#2020022, #2020023, #2022083). The work was partly performed on the Services for sensitive data (TSD), University of Oslo, Norway, with resources provided by UNINETT Sigma2 - the National Infrastructure for High Performance Computing and Data Storage in Norway. MoBa is supported by the Norwegian Ministry of Health and Care Services and the Ministry of Education and Research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The establishment of the MoBa cohort and initial data collection was based on a license from the Norwegian Data Protection Agency and approval from The Regional Committees for Medical and Health Research Ethics (REC). MoBa follows regulations from the Norwegian Health Registry Act. The current study was approved by the administrative board of MoBa led by NIPH and The Regional Committees for Medical and Health Research Ethics (2016/1226/REK Sor-ost C).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes